Literature DB >> 29997968

Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule.

Jong Hui Suh1, Jae Kil Park2, Youngkyu Moon2.   

Abstract

BACKGROUND: Clinical stage IA lung cancer presenting as a ground glass opacity (GGO) on imaging is known to be associated with a good prognosis. Conversely, the prognosis of lung cancer presenting as a pure solid nodule is less favorable. The purpose of this study was to identify the predictive factors affecting prognosis in pure solid nodule lung cancer.
METHODS: A total of 328 consecutive patients undergoing curative resection of clinical stage IA pure solid nodule lung cancer were reviewed retrospectively. Recurrence, survival and risk factors for nodal upstaging were analyzed.
RESULTS: Of the 328 patients, 277 patients (84.6%) underwent lobectomy (or greater) and 51 patients (15.6%) underwent sublobar resection. Mediastinal lymph node dissection or sampling was performed in 278 patients (84.8%). The 5-year recurrence-free survival rate was 70.0% and the disease-specific survival rate was 86.5%. Intraoperative mediastinal lymph node dissection was the only significant related factor for recurrence and cancer-related death in a multivariate analysis [hazard ratio (HR) =0.485, P=0.020; HR =0.342, P=0.014]. A total of 217 patients underwent lobectomy with mediastinal lymph node dissection and nodal upstaging occurred in 36 patients (16.6%). There were no significant predictive factors for nodal upstaging in a multivariate analysis. Visceral pleural invasion, lymphovascular invasion, and small cell carcinoma histology were the only identified risk factors for nodal upstaging (HR =3.858, P=0.006; HR =8.792, P<0.001; HR =45.908, P=0.017).
CONCLUSIONS: There were no definite factors predictive of prognosis in clinical stage IA pure solid nodule lung cancer. Only accurate pathologic staging and adequate intraoperative lymph node dissection were shown to be related to prognosis.

Entities:  

Keywords:  Oncology; lung cancer; thoracic surgery

Year:  2018        PMID: 29997968      PMCID: PMC6006101          DOI: 10.21037/jtd.2018.05.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  34 in total

Review 1.  Sublobar resection: a movement from the Lung Cancer Study Group.

Authors:  Justin D Blasberg; Harvey I Pass; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

Review 2.  What is the most practical, optimal, and cost effective method for performing follow-up after lung cancer surgery, and by whom should it be done?

Authors:  Lise Tremblay; Jean Deslauriers
Journal:  Thorac Surg Clin       Date:  2013-06-28       Impact factor: 1.750

3.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L).

Authors:  Kenichi Nakamura; Hisashi Saji; Ryu Nakajima; Morihito Okada; Hisao Asamura; Taro Shibata; Shinichiro Nakamura; Hirohito Tada; Masahiro Tsuboi
Journal:  Jpn J Clin Oncol       Date:  2009-11-22       Impact factor: 3.019

4.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

5.  Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non-small cell lung cancer.

Authors:  Shuenn-Wen Kuo; Jin-Shing Chen; Pei-Ming Huang; Hsao-Hsun Hsu; Hong-Shiee Lai; Jang-Ming Lee
Journal:  J Thorac Cardiovasc Surg       Date:  2014-04-23       Impact factor: 5.209

6.  Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience.

Authors:  Junji Yoshida; Kanji Nagai; Tomoyuki Yokose; Mitsuyo Nishimura; Ryutaro Kakinuma; Hironobu Ohmatsu; Yutaka Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

7.  Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules.

Authors:  Jong Ho Cho; Yong Soo Choi; Jhingook Kim; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim
Journal:  Ann Thorac Surg       Date:  2014-11-15       Impact factor: 4.330

8.  Surgical outcomes in lung cancer presenting as ground-glass opacities of 3 cm or less: a review of 5 years' experience.

Authors:  Chi-Wei Duann; Jung-Jyh Hung; Po-Kuei Hsu; Chien-Sheng Huang; Chih-Cheng Hsieh; Han-Shui Hsu; Yu-Chung Wu; Wen-Hu Hsu
Journal:  J Chin Med Assoc       Date:  2013-10-04       Impact factor: 2.743

9.  Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings.

Authors:  Yasuhiro Tsutani; Yoshihiro Miyata; Takeharu Yamanaka; Haruhiko Nakayama; Sakae Okumura; Shuji Adachi; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-13       Impact factor: 5.209

10.  Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications.

Authors:  Hyun-Ju Lim; Soomin Ahn; Kyung Soo Lee; Joungho Han; Young Mog Shim; Sookyoung Woo; Jae-Hun Kim; Miyeon Yie; Ho Yun Lee; Chin A Yi
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

View more
  3 in total

1.  Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

2.  Prognosis of upstaged N1 and N2 disease after curative resection in patients with clinical N0 non-small cell lung cancer.

Authors:  Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  Volumetric assessment of solid pulmonary nodules on ultralow-dose CT: a phantom study.

Authors:  Matthias Eberhard; Daniel Stocker; Gianluca Milanese; Katharina Martini; Thi Dan Linh Nguyen-Kim; Moritz C Wurnig; Thomas Frauenfelder; Stephan Baumueller
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.